The Cooper Companies Faces CEO Transition Amid Slowing Demand Forecasts

The Cooper Companies, Inc. recently experienced a significant shift in leadership after Albert White stepped down from his roles as president and chief executive officer. Board member Walter Rosebrough has taken over executive chair duties to oversee day-to-day operations as the company implements broader board changes.

The leadership shakeup comes as market observers express caution over the medical device maker's financial path. StockStory highlighted an absence of organic revenue growth over the past two years, projecting estimated sales growth of 2.9% for the coming 12 months. Reporting from Barchart noted that analysts anticipate annual sales growth of 4.2% next year, lower than the company's two-year trend of nearly 6.5%, alongside below-average returns on capital.

Wall Street analysts hold a consensus "Hold" rating on the stock, according to Barchart. Of the 18 analysts tracking the firm, four assign a "Strong Buy," one recommends a "Moderate Buy," 11 suggest a "Hold," and two advise a "Strong Sell." The group's average price target stands at $65.25. Meanwhile, an investor valuation narrative published by Yahoo Finance calculated a fair value of about $66.21, citing operational efficiency efforts and expectations for about US$2.2b in free cash flow from 2026 to 2028.

Expectations for the upcoming fourth-quarter 2026 earnings report remain measured. Diluted earnings per share are projected by analysts to hit $1.07, down 7% from $1.15 in the prior-year period. However, for the full fiscal year 2026, analysts anticipate diluted earnings per share of $4.53, followed by a roughly 3.5% rise to $4.69 in fiscal 2027.

These recent headwinds follow an earlier setback on September 9, 2026, when the company terminated a nine-month strategic review to sell its CooperSurgical business after acquisition offers fell short of board expectations. To counter operational softness and support shareholders, the board authorized a new $1 billion share repurchase program alongside the retention of the surgical division.